NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer

SIMPLE SUMMARY: The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma. Patients with locoregional, pathologically high-risk disease recur frequently despite adjuvant cisplatin–radiation therapy. Targeting PD1 may reverse immuno...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancers (Basel)
Autors principals: Bauman, Julie E., Harris, Jonathan, Uppaluri, Ravindra, Yao, Min, Ferris, Robert L., Chen, Josephine, Jordan, Richard C., Joshi, Nikhil P., Jujjuvaparu, Srinivas, Blakaj, Dukagjin M., Henson, Christina, Sheqwara, Jawad, Mell, Loren K., Sen, Neilayan, Clump, David A., Garg, Madhur K., Yilmaz, Emrullah, Torres-Saavedra, Pedro, Le, Quynh-Thu
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8230356/
https://ncbi.nlm.nih.gov/pubmed/34207599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13122882
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars